Cytosorbents (CTSO)
(Real Time Quote from BATS)
$0.81 USD
-0.01 (-1.42%)
Updated Apr 25, 2024 12:38 PM ET
NA Value
NA Growth NA Momentum NA VGMBalance Sheet
Fiscal Year End for Cytosorbents Corporation falls in the month of December.
All items in Millions except Per Share data.
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | 14 | 22 | 52 | 71 | 12 |
Receivables | 6 | 6 | 5 | 5 | 4 |
Notes Receivable | 0 | 0 | 0 | 0 | 0 |
Inventories | 4 | 3 | 5 | 3 | 2 |
Other Current Assets | 2 | 2 | 3 | 3 | 2 |
Total Current Assets | 26 | 34 | 64 | 82 | 21 |
Net Property & Equipment | 10 | 11 | 5 | 2 | 2 |
Investments & Advances | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Assets | 0 | 0 | 0 | 0 | 0 |
Deferred Charges | 0 | 0 | 0 | 0 | 0 |
Intangibles | 0 | 0 | 0 | 0 | 0 |
Deposits & Other Assets | 5 | 6 | 7 | 4 | 3 |
Total Assets | 53 | 63 | 90 | 90 | 27 |
Liabilities & Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Notes Payable | 0 | 0 | 0 | 0 | 0 |
Accounts Payable | 4 | 2 | 3 | 2 | 2 |
Current Portion Long-Term Debt | 3 | 0 | 0 | 0 | 2 |
Current Portion Capital Leases | 0 | 0 | 0 | 0 | 0 |
Accrued Expenses | 8 | 8 | 10 | 8 | 6 |
Income Taxes Payable | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Total Current Liabilities | 15 | 10 | 14 | 10 | 10 |
Mortgages | 0 | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | 0 | 0 | 0 | 0 | 0 |
Convertible Debt | 0 | 0 | 0 | 0 | 0 |
Long-Term Debt | 3 | 5 | 0 | 0 | 13 |
Non-Current Capital Leases | 0 | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 |
Minority Interest (Liabilities) | 0 | 0 | 0 | 0 | 0 |
Total Liabilities | 30 | 28 | 27 | 11 | 24 |
Shareholders Equity | 12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 |
---|---|---|---|---|---|
Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock (Par) | 0 | 0 | 0 | 0 | 0 |
Capital Surplus | 305 | 287 | 283 | 278 | 192 |
Retained Earnings | -283 | -254 | -221 | -197 | -189 |
Other Equity | 1 | 2 | 1 | -2 | 1 |
Treasury Stock | 0 | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | 23 | 35 | 63 | 79 | 3 |
Total Liabilities & Shareholder's Equity | 53 | 63 | 90 | 90 | 27 |
Total Common Equity | 23 | 35 | 63 | 79 | 3 |
Shares Outstanding | 44.40 | 43.60 | 43.40 | 43.10 | 32.40 |
Book Value Per Share | 0.52 | 0.81 | 1.44 | 1.84 | 0.11 |
Fiscal Year End for Cytosorbents Corporation falls in the month of December.
All items in Millions except Per Share data.
3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
---|---|---|---|---|---|
Assets | |||||
Cash & Equivalents | -99,999 | 14 | 8 | 13 | 19 |
Receivables | NA | 6 | 6 | 7 | 6 |
Notes Receivable | NA | 0 | 0 | 0 | 0 |
Inventories | NA | 4 | 3 | 2 | 2 |
Other Current Assets | NA | 2 | 2 | 1 | 2 |
Total Current Assets | NA | 26 | 19 | 24 | 28 |
Net Property & Equipment | NA | 10 | 10 | 11 | 11 |
Investments & Advances | NA | 0 | 0 | 0 | 0 |
Other Non-Current Assets | NA | 0 | 0 | 0 | 0 |
Deferred Charges | NA | 0 | 0 | 0 | 0 |
Intangibles | NA | 0 | 0 | 0 | 0 |
Deposits & Other Assets | NA | 5 | 6 | 6 | 6 |
Total Assets | NA | 53 | 48 | 52 | 57 |
Liabilities & Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Notes Payable | NA | 0 | 0 | 0 | 0 |
Accounts Payable | NA | 4 | 3 | 3 | 3 |
Current Portion Long-Term Debt | NA | 3 | 1 | 0 | 0 |
Current Portion Capital Leases | NA | 0 | 0 | 0 | 0 |
Accrued Expenses | NA | 8 | 8 | 7 | 7 |
Income Taxes Payable | NA | 0 | 0 | 0 | 0 |
Other Current Liabilities | NA | 0 | 0 | 0 | 0 |
Total Current Liabilities | NA | 15 | 12 | 10 | 10 |
Mortgages | NA | 0 | 0 | 0 | 0 |
Deferred Taxes/Income | NA | 0 | 0 | 0 | 0 |
Convertible Debt | NA | 0 | 0 | 0 | 0 |
Long-Term Debt | NA | 3 | 4 | 5 | 5 |
Non-Current Capital Leases | NA | 0 | 0 | 0 | 0 |
Other Non-Current Liabilities | NA | 0 | 0 | 0 | |
Minority Interest (Liabilities) | NA | 0 | 0 | 0 | 0 |
Total Liabilities | NA | 30 | 29 | 28 | 29 |
Shareholders Equity | 3/31/2024 | 12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 |
---|---|---|---|---|---|
Preferred Stock | NA | 0 | 0 | 0 | 0 |
Common Stock (Par) | NA | 0 | 0 | 0 | 0 |
Capital Surplus | NA | 305 | 292 | 290 | 289 |
Retained Earnings | NA | -283 | -277 | -267 | -261 |
Other Equity | NA | 1 | 3 | 1 | 2 |
Treasury Stock | NA | 0 | 0 | 0 | 0 |
Total Shareholder's Equity | NA | 23 | 19 | 24 | 29 |
Total Liabilities & Shareholder's Equity | NA | 53 | 48 | 52 | 57 |
Total Common Equity | 0 | 23 | 19 | 24 | 29 |
Shares Outstanding | 54.20 | 44.40 | 44.30 | 43.90 | 43.90 |
Book Value Per Share | 0.00 | 0.52 | 0.42 | 0.55 | 0.66 |